Diamyd
- Generic Name
- Diamyd
Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals At Risk for Type 1 Diabetes
Phase 2
Recruiting
- Conditions
- Diabetes Mellitus, Type 1PreventionAutoimmune Diseases
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Diamyd Medical AB
- Target Recruit Count
- 16
- Registration Number
- NCT05683990
- Locations
- 🇸🇪
Lund University/CRC, Skåne University Hospital,, Malmö, Sweden
EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2021-03-29
- Lead Sponsor
- Johnny Ludvigsson
- Target Recruit Count
- 20
- Registration Number
- NCT02464033
- Locations
- 🇸🇪
Uddevalla Hospital, Uddevalla, Sweden
🇸🇪Helsingborg Hospital, Helsingborg, Sweden
🇸🇪Lund University Hospital, Lund, Sweden
GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1)
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Johnny Ludvigsson
- Target Recruit Count
- 12
- Registration Number
- NCT02352974
- Locations
- 🇸🇪
Linköping University, Linköping, Sweden
Diabetes Virus Detection Project, Intervention With GAD-alum
Phase 2
Terminated
- Conditions
- AutoimmunityEnterovirus InfectionsDiabetes, Type I
- Interventions
- Other: Placebo
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT01129232
- Locations
- 🇳🇴
Endokrinologisk poliklinikk, Oslo Universitetssykehus Aker, Oslo, Norway
Diabetes Prevention - Immune Tolerance
Phase 2
Completed
- Conditions
- PrediabetesType 1 Diabetes
- Interventions
- Other: Placebo comparator
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Lund University
- Target Recruit Count
- 50
- Registration Number
- NCT01122446
- Locations
- 🇸🇪
Clinical Research Center, Pediatric Endocrinology, Jan Waldenströms gata 35, 60:11, Malmö, Sweden
Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects
Phase 2
Completed
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2020-05-07
- Target Recruit Count
- 145
- Registration Number
- NCT00529399
- Locations
- 🇺🇸
Childrens Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸University of California-San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath